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Generalized Pyoderma Gangrenosum Associated with 
Ulcerative Colitis: Successful Treatment with Inflix-
imab and Azathioprine 
Pyoderma gangrenosum (PG) is a rare ulcerative 
skin disease, part of the spectrum of neutrophilic and 
auto-inflammatory dermatoses. Its pathogenesis is 
unknown, although immune pathways have been 
implicated. Lesion biopsies show a predominantly 
neutrophilic infiltrate. The incidence of PG is uncer-
tain, but it is estimated to be 3-10 per million per year, 
occurring at any age but most commonly between 20 
and 50 years with a possible slightly higher incidence 
in women. Approximately 50% of patients with PG 
also have another disease associated with PG. The 
most common is inflammatory bowel disease (IBD), 
particularly Crohn’s and ulcerative colitis (UC). Local 
treatment may be sufficient for mild cases, while for 
severe cases systemic immunosuppressants are the 
mainstay (1,2). We report the case of a patient with 
bullous PG and UC successfully treated with inflix-
imab and azathioprine. 
A 32-year-old male Caucasian patient presented 
with painful violaceous vesicles and enlarging bullae 
of various sizes and with acute onset, located on the 
trunk and bilaterally on both the lower and the upper 
extremities. Lesions on the trunk were composed of 
hemorrhagic pustules with a surrounding erythema-
tous overhanging border. Some of the lesions had 
undergone central necrosis and ulceration (Figure 1, 
a-d). The patient reported of the lesions had appeared 
one week ago, simultaneously with the exacerbation 
of a known inflammatory bowel disease with hemor-
rhagic mucoid diarrhea and fever of up to 38.5°C. The 
patient’s medical history included UC affecting the 
whole colon (pancolitis), diagnosed 5 months prior 
to the onset of the epidermal lesions, for which the 
patient was receiving treatment with oral predniso-
lone 10 mg/day and mesalazine granules.
Blood tests showed severe anemia, leukocytosis, 
and increased inflammatory markers (C-reactive pro-
tein, erythrocyte sedimentation rate). Antinuclear 
antibodies (ANA), anti-double stranded DNA (anti-
dsDNA) andtibodies, antineutrophil cytoplasmic an-
Figure 1. Large, rapidly progressing lesions of pyoderma gangrenosum on the lower extremities (a-b) and on the trunk (c-d) 
before treatment.
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tibodies (cANCA), perinuclear neutrophil antibodies 
(p-ANCA), antiphospholipid antibodies, and tumor 
markers were within normal limits. The patient was 
negative for cryoglobulins, viral hepatitis (B, C) and 
human immunodeficiency virus (HIV). Blood cultures 
were negative. Microscopy and cultures for mycobac-
teria and fungi gave negative results. Stool samples 
tested negative for infections agents. The Mantoux 
skin test was negative. Colonoscopy showed severe 
pancolitis, and biopsies from the rectum and sigmoid 
colon were consistent with chronic ulcerative colitis. 
Abdominal ultrasound and chest and abdominal X-
rays did not result in significant findings. Because of 
severe anemia, the patient received 2 blood transfu-
sions. The histopathologic examination carried out 
on the erythematous border of a lesion on the lower 
leg showed a neutrophilic infiltrate, confined to the 
dermis. On the basis of clinical findings, the diagnosis 
of PG was established.
Topical wound care consisted of local wound care 
and a topical corticosteroid. Systemic therapy was ini-
tiated with 40 mg/day methylprednisolone for 7 days, 
30 mg/day for 7 days, then 25 mg/day, and then ta-
pered down further. The patient received an infusion 
of infliximab 7.5 mg/kg at weeks 0, 2, and 6 and every 
8 weeks thereafter. After week 2, oral azathioprine 2.5 
mg/kg daily was added to the treatment. The patient 
also received mesalazine tablets (2 g ×2/day) and me-
salazine enema (1-2/day). The patient showed good 
response to treatment, with clinical remission of skin 
lesions. Lesions healed with characteristic thin, atro-
phic scars (Figure 2, a-d). At 7-month follow-up  the 
patient was continuing with infusions of infliximab 
7.5 mg/kg and azathioprine 2.5 mg/kg and was still 
in remission.
We reported our experience with a case of gen-
eralized bullous pyoderma gangrenosum associ-
ated with ulcerative colitis. Generalized pyoderma 
gangrenosum is very rare. Bullous or atypical PG was 
first described by Perry and Winklemann in 1972 (1). 
Brunsting et al. coined the term pyoderma gangreno-
sum (PG) to describe a series of patients with recur-
rent ulcerations (3). The incidence of this disease is 
uncertain. Its pathogenesis is unknown, but an im-
munological background has been suggested. In 
approximately 50% of patients, an underlying immu-
nological disease is present, commonly inflammatory 
bowel disease (IBD) (4-6). In larger series of patients 
with PG, approximately 50% present with a primary 
disorder. Ulcerative colitis is found in 10-15% of cases. 
Crohn’s disease is associated with PG closed than UC. 
Less than 3% of patients with Crohn’s disease or UC 
develop PG (6). 
PG is characterized by cutaneous ulcerations with 
mucopurulent or hemorrhagic exudate. It begins as 
an inflammatory pustule with a surrounding halo 
that enlarges and begins to ulcerate. These very pain-
ful ulcers present with undermined bluish borders 
with surrounding erythema. The lesions of PG most 
commonly occur on the legs, but they may occur any-
where on the body. The clinical picture of PG is very 
characteristic. Therefore the diagnosis of PG is based 
firstly on clinical signs and on the patient’s history of 
underlying diseases and then supported by biopsy. 
PG has four distinctive clinical and histological vari-
ants. Some have morphological and histological fea-
tures that overlap with other reactive neutrophilic 
skin conditions. There are no diagnostic serologic 
features (6,7). 
There is no evidence that the efficacy of treatment 
strategies for PG differs between IBD and non-IBD pa-
tients. For patients with a diffuse disease or rapidly 
progressive process, systemic treatment is essential. 
Immunosuppression is the mainstay of treatment. 
Traditionally, the most commonly used drugs with 
the best clinical experience are systemic corticoste-
roids. Corticosteroids have been considered as first 
line treatment (6,8). As reported by the European 
Crohn’s and Colitis Organisation (ECCO) in 2008, an 
Figure 2. Clinical remission of skin lesions on the lower ex-
tremities (a-b) and on the trunk (c-d) after treatment with 4 
infliximab infusions and azathioprine.
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evidence-based consensus on the management of 
special situations in patients with ulcerative colitis, 
systemic corticosteroids are recommended (9). Treat-
ment with corticosteroids (e.g. prednisolone 1-2 mg 
per kg/day or pulse therapy with 1 g of methylpred-
nisolone) aims to prevent progression and rapidly 
stop inflammation (6). Additional mesalamine and 
corticosteroids may be effective in patients with 
bowel disease (10).
In recent years, tumor necrosis alpha (TNF-α) in-
hibitors, such as infliximab and adalimumab, were 
reported to be effective for PG associated with IBD. 
These drugs block the biological activity of TNF-α, 
which effects regulatory T cells, restoring their capac-
ity to inhibit cytokine production. The TNF-α inhibi-
tors thus suppress the inflammatory processes that is 
involved in the pathogenesis of PG (11). Infliximab, a 
chimeric monoclonal antibody, is given by infusion at 
weeks 0, 2, and 6 and then every 8 weeks, usually at a 
dosage of 5 mg/kg. 
UC of patients with frequent disease relapse or 
those that are resistant or dependent on corticoste-
roids is often treated with purine antimetabolites, 
such as azathioprine (AZA) (10). AZA, a purine anti-
metabolite (2.5 mg per kg/day) is administered for its 
steroid-sparing effects. The response occurs after 2 
to 4 weeks (6, 10). Infliximab can be combined with 
AZA. Patients with UC treated with infliximab plus 
AZA were more likely to achieve corticosteroid-free 
remission at 16 weeks than those receiving either 
monotherapy (10,12).
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